- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
XVIVO Capital Markets Day 2022
XVIVO invites to its digital Capital Markets Day, September 21, 2022. Dag Andersson, CEO, and members of the XVIVO management team will cover company strategy, financials and operations momentum. Dr. David McGiffin, Australia, will join as a guest speaker. He will present his experience with the XVIVO Heart technology as the coordinating principal investigator of the ANZ NIHP clinical trial.
Location: Online
Date: Wednesday, September 21, 2022
Time: 14:00 – 16:00 CEST
Agenda
14:00 – 14:20 Strategy and Financials
Presenters: Dag Andersson, CEO & Kristoffer Nordström, CFO
14:20 – 14:40 Machine perfusion strategy
Presenter: Johan Holmström, CCO
14:40 – 15:00 Beyond product: STAR Teams and Avionord M&P
Presenter: Christoffer Rosenblad, COO
15:00 – 15:15 Regulatory strategy
Presenter: Katrin Gisselfält, Global Quality Assurance & Regulatory Affairs Director
15:15 – 15:45 XVIVO Heart technology: The power of oxygenation & clinical trials
Presenters: Andreas Wallinder, CMO & Jaya Tiwari, Vice President Clinical and Regulatory Affairs US
Guest speaker: Dr. David McGiffin, Professor of Cardiothoracic Surgery and Transplantation at Alfred Health, Melbourne, Australia
15:45 – 16:00 Q&A session
Registration
The Capital Markets Day will be broadcasted live online. Please register to the event via this link.
A recording of the Capital Markets Day will be available on-demand on our website shortly after the event.
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
